Recurrent Ovarian Cancer: PARP Inhibitors Compared

Ovarian Cancer and Tumor Treating Fields | Oncology Today with Dr Neil Love — Role of PARP Inhibi...Подробнее

Recurrent Ovarian Cancer (2022)Подробнее

Ovarian Cancer Treatments, Research and Survivorship Updates 2022Подробнее

The Advanced Ovarian Cancer Treatment Palette: Candid Conversations on PARP InhibitorsПодробнее

PARP INHIBITORS: REDUCING OVARIAN CANCER RECURRENCE RISKПодробнее

PARP Inhibitors: Reducing Ovarian Cancer Recurrence RiskПодробнее

Updates in Treatment of Ovarian Cancer: PARP InhibitorsПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее

Latest updates in low grade serous ovarian cancer treatment and researchПодробнее

Updates in ovarian cancer research, with Dr Rowan MillerПодробнее

PARP Inhibition’s Role in Recurrent Ovarian CancerПодробнее

Strategies for Managing Recurrent Ovarian CancerПодробнее

Recurrent Ovarian Cancer: Choosing a PARP InhibitorПодробнее

3/26/2021: Upfront Treatment of Advanced Ovarian Cancer; Ay, Now the Plot ThickensПодробнее

Olaparib With or W/out Cediranib vs Standard of Care for Recurrent Platinum-Sensitive Ovarian CancerПодробнее

PARP Inhibitors in Recurrent Ovarian CancerПодробнее

Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical OncologistПодробнее

Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian CancerПодробнее

Bevacizumab’s Role in Recurrent Ovarian CancerПодробнее